#292 COVID-19 Vaccine Adverse Events
CLINICAL QUESTION
What does real world evidence tell us about adverse effects from available COVID-19 vaccines?
BOTTOM LINE
Best evidence finds systemic adverse events related to COVID-19 vaccines are mostly short-lived and differ by type of vaccine, dose given, age, and gender. Anaphylaxis to mRNA vaccines occurs in 2.5 to 5 per million doses. Vaccine-induced thrombotic thrombocytopenia (VITT) is associated with viral vector vaccines (AstraZeneca or Johnson and Johnson). Best estimates of incidence: ~0.5 to 2 per 100,000 and more commonly in women.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- From published prospective or retrospective cohort/case control studies.
- General systemic adverse events:
- Best evidence from solicited adverse events up to 8 days post-dose in 655,590 patients with Pfizer (2 doses) or AstraZeneca (1 dose) adults:1
- Most commonly short lived and last 1-2 days:
- Fatigue, headache: Each 13-23%.
- Adverse events more common among:
- Recipients of AstraZeneca (versus Pfizer), Pfizer second dose versus first.
- Individuals 55 or younger.
- Women.
- Similar findings in clinical trials.2
- Anaphylaxis risk: Based on ~10 million Pfizer doses, ~8 million Moderna.3
- Incidence (per million doses): 5 (Pfizer), 2.5 (Moderna).
- 1/3 reported previous anaphylaxis episodes, ~80% with known allergies.
- No deaths reported.
- Incidence (per million doses): 5 (Pfizer), 2.5 (Moderna).
- Most commonly short lived and last 1-2 days:
- Best evidence from solicited adverse events up to 8 days post-dose in 655,590 patients with Pfizer (2 doses) or AstraZeneca (1 dose) adults:1
- VITT:
- VITT leading to rare thromboses, particularly cerebral venous sinus thrombosis (CVST), 4-28 days post AstraZeneca vaccine.
- Risk varies4,5 from 0.4 per 100,000 in 80+ years to ~2 per 100,000 in 20-49.
- Majority in women under 60 within 14 days of vaccination.5
- Cohort of 281,264 AstraZeneca recipients in Denmark/Norway6 calculated thrombosis events in excess of natural background risk:
- Additional venous thromboembolisms (includes deep venous thrombosis, pulmonary embolism and CVST) possibly attributed to vaccine: 11 per 100,000 doses and mostly in women.
- VITT leading to rare thromboses, particularly cerebral venous sinus thrombosis (CVST), 4-28 days post AstraZeneca vaccine.
- Suspect VITT if AstraZeneca or Johnson & Johnson vaccine 4-28 days prior, signs/symptoms or positive imaging of serious thrombosis with thrombocytopenia.7
- Diagnosis confirmed with positive heparin-induced thrombocytopenia assay.4,7
- Clinical pathways available to guide approach to suspected VITT8: https://is.gd/71P7I2
- Patient decision tool for AstraZeneca vaccine available:9 https://is.gd/Bn4EPJ
- To report possible vaccine related adverse events in Canada:10 https://is.gd/LwKQNDl
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
good information
excellent information
Good
Very relevant to my practice
Very releavnt to my practice
Very relevant to my practice